About AC Immune
AC Immune is a company based in Lausanne (Switzerland) founded in 2003.. AC Immune has raised $119.82 million across 9 funding rounds from investors including Lilly, The Michael J. Fox Foundation and BVF Partners. The company has 172 employees as of December 31, 2024. AC Immune offers products and services including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform. AC Immune operates in a competitive market with competitors including BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others.
- Headquarter Lausanne, Switzerland
- Employees 172 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ac Immune Sa
-
Annual Revenue
$31.01 M88.28as on Dec 31, 2024
-
Net Profit
$-57.82 M4.2as on Dec 31, 2024
-
EBITDA
$-57.18 M2.85as on Dec 31, 2024
-
Total Equity Funding
$119.82 M (USD)
in 9 rounds
-
Latest Funding Round
-
Investors
Lilly
& 4 more
-
Employee Count
172
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AC Immune
AC Immune is a publicly listed company on the NASDAQ with ticker symbol ACIU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AC Immune
AC Immune offers a comprehensive portfolio of products and services, including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments targeting proteins in neurodegenerative diseases.
Facilitates creation of small molecule drugs for disease treatment.
Enables development of biologics for neurodegenerative therapies.
Unlock access to complete
Unlock access to complete
Funding Insights of AC Immune
AC Immune has successfully raised a total of $119.82M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Last Round
-
First Round
First Round
(01 Jul 2003)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Post-IPO - AC Immune | Valuation |
investors |
|
| Sep, 2022 | Amount | Grant - AC Immune | Valuation |
investors |
|
| Sep, 2019 | Amount | Grant - AC Immune | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AC Immune
AC Immune has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, The Michael J. Fox Foundation and BVF Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AC Immune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AC Immune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ac Immune Comparisons
Competitors of AC Immune
AC Immune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Medicines are developed to protect, repair, and restore hearing capacity.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ac Immune
Frequently Asked Questions about AC Immune
When was AC Immune founded?
AC Immune was founded in 2003.
Where is AC Immune located?
AC Immune is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Who is the current CEO of AC Immune?
Andrea Pfeifer is the current CEO of AC Immune.
Is AC Immune a funded company?
AC Immune is a funded company, having raised a total of $119.82M across 9 funding rounds to date.
How many employees does AC Immune have?
As of Dec 31, 2024, the latest employee count at AC Immune is 172.
What is the annual revenue of AC Immune?
Annual revenue of AC Immune is $31.01M as on Dec 31, 2024.
What does AC Immune do?
AC Immune was founded in 2003 in Lausanne, Switzerland, within the biotechnology sector. Focus is placed on developing antibodies, small molecules, and vaccines targeting Alzheimers disease, Parkinsons, Down syndrome, and glaucoma. A diversified pipeline is maintained, supported by technology platforms such as SupraAntigen for diagnostics and biologics, and Morphomer for small molecule drugs. Operations emphasize neurodegenerative disorders through research and therapeutic innovation.
Who are the top competitors of AC Immune?
AC Immune's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
What products or services does AC Immune offer?
AC Immune offers Active Immunotherapies, Morphomer Platform, and Supraantigen Platform.
Is AC Immune publicly traded?
Yes, AC Immune is publicly traded on NASDAQ under the ticker symbol ACIU.
Who are AC Immune's investors?
AC Immune has 5 investors. Key investors include Lilly, The Michael J. Fox Foundation, BVF Partners, Avidity Partners, and Redmile Group.
What is AC Immune's ticker symbol?
The ticker symbol of AC Immune is ACIU on NASDAQ.